CSL pre-empts TGA review outcome

By Megan Brodie 4 weeks ago | In Regulatory, Reputation
  • 4 weeks ago

16 October 2026 CSL has announced it is withdrawing TAVNEOS (avacopan) from the Australian market…

This is subscriber-only content. Please login to continue reading.